Mark Mitton-Fry, PhD

Associate Professor

Medicinal Chemistry and Pharmacognosy

Research Areas: Infectious Diseases, Division of Medicinal Chemistry & Pharmacognosy

Parks Hall

(614) 292-1903

Professional Interests

Dr. Mitton-Fry’s research team is dedicated to inventing cures for multidrug-resistant bacterial infections. The lab uses the tools of synthetic medicinal chemistry to design and prepare innovative new molecules, and we collaborate broadly to evaluate their biological, pharmaceutical, and toxicological properties. Dr. Mitton-Fry also enjoys teaching students at all levels about antibacterial therapies.

Education

2002, PhD, University of Colorado Boulder
1996, BA, Carleton College

Publications

Actions of a Novel Bacterial Topoisomerase Inhibitor against Neisseria gonorrhoeae Gyrase and Topoisomerase IV: Enhancement of Double-Stranded DNA Breaks, International Journal of Molecular Sciences. 2023 Jan | journal-article. doi: 10.3390/ijms241512107.
Antibacterial activity of novel bacterial topoisomerase inhibitors against key veterinary pathogens, Veterinary Microbiology. 2023 Jan | journal-article. doi: 10.1016/j.vetmic.2023.109840.
Serendipitous Discovery of a Competitive Inhibitor of FraB, a Salmonella Deglycase and Drug Target, Pathogens. 2022 Sep | journal-article. doi: 10.3390/pathogens11101102.
Aryl Methyl Ketones: Versatile Synthons in the Synthesis of Heterocyclic Compounds, SynOpen. 2022 Jun | journal-article. doi: 10.1055/a-1826-2852.
1,3-Dioxane-Linked Novel Bacterial Topoisomerase Inhibitors: Expanding Structural Diversity and the Antibacterial Spectrum, ACS Medicinal Chemistry Letters. 2022 May | journal-article. doi: 10.1021/acsmedchemlett.2c00111.
Dioxane-Linked Novel Bacterial Topoisomerase Inhibitors Exhibit Bactericidal Activity against Planktonic and Biofilm Staphylococcus aureus In Vitro, Microbiology Spectrum. 2022 Jan | journal-article. doi: 10.1128/spectrum.02056-22.
Optimization of TopoIV Potency, ADMET Properties, and hERG Inhibition of 5-Amino-1,3-dioxane-Linked Novel Bacterial Topoisomerase Inhibitors: Identification of a Lead with In Vivo Efficacy against MRSA., Journal of medicinal chemistry. 2021 Oct | journal-article. doi: 10.1021/acs.jmedchem.1c01250.
Novel bacterial topoisomerase inhibitors derived from isomannide., European journal of medicinal chemistry. 2020 Apr | journal-article. doi: 10.1016/j.ejmech.2020.112324.
Dioxane-Linked Amide Derivatives as Novel Bacterial Topoisomerase Inhibitors against Gram-Positive Staphylococcus aureus, ACS Medicinal Chemistry Letters. 2020 Jan | journal-article. doi: 10.1021/acsmedchemlett.0c00428.
1,3-Dioxane-Linked Bacterial Topoisomerase Inhibitors with Enhanced Antibacterial Activity and Reduced hERG Inhibition, . 2019 May | journal-article. doi: 10.1021/acsinfecdis.8b00375.
Process Development for the Synthesis of Monocyclic β-Lactam Core 17, Organic Process Research & Development. 2018 Jan | journal-article. doi: 10.1021/acs.oprd.7b00359.
Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases, Journal of Medicinal Chemistry. 2018 Jan | journal-article. doi: 10.1021/acs.jmedchem.7b01598.
Synthesis and anti-staphylococcal activity of novel bacterial topoisomerase inhibitors with a 5-amino-1,3-dioxane linker moiety, Bioorganic and Medicinal Chemistry Letters. 2018 Jan | journal-article. doi: 10.1016/j.bmcl.2018.06.003.
Novel Bacterial Type II Topoisomerase Inhibitors, 2017 Medicinal Chemistry Reviews. 2017 Nov | other. doi: 10.29200/acsmedchemrev-v52.ch15.
Novel 3-fluoro-6-methoxyquinoline derivatives as inhibitors of bacterial DNA gyrase and topoisomerase IV, Bioorganic & Medicinal Chemistry Letters. 2017 Aug | journal-article. doi: 10.1016/j.bmcl.2017.06.009.
Corrigendum to "Novel monobactams utilizing a siderophore uptake mechanism for the treatment of Gram-negative infections" [Bioorg. Med. Chem. Lett. 22/18 (2012) 5989-5994], Bioorganic and Medicinal Chemistry Letters. 2015 Jan | journal-article. doi: 10.1016/j.bmcl.2015.07.024.
Oclacitinib (APOQUEL^®) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy, Journal of Veterinary Pharmacology and Therapeutics. 2014 Jan | journal-article. doi: 10.1111/jvp.12101.
Pyridone-Conjugated Monobactam Antibiotics with Gram-Negative Activity, Journal of Medicinal Chemistry. 2013 Jul | journal-article. doi: 10.1021/jm400560z.
Novel quinoline derivatives as inhibitors of bacterial DNA gyrase and topoisomerase IV, Bioorganic and Medicinal Chemistry Letters. 2013 Jan | journal-article. doi: 10.1016/j.bmcl.2013.03.047.
Heterocyclic methylsulfone hydroxamic acid LpxC inhibitors as Gram-negative antibacterial agents, Bioorganic & Medicinal Chemistry Letters. 2012 Nov | journal-article. doi: 10.1016/j.bmcl.2012.09.058.
Total synthesis of (±)-monomorine, Tetrahedron Letters. 2012 Oct | journal-article. doi: 10.1016/j.tetlet.2012.08.041.
Rapid Evaluation in Whole Blood Culture of Regimens for XDR-TB Containing PNU-100480 (Sutezolid), TMC207, PA-824, SQ109, and Pyrazinamide, PLoS ONE. 2012 Jan | journal-article. doi: 10.1371/journal.pone.0030479.
Novel monobactams utilizing a siderophore uptake mechanism for the treatment of gram-negative infections, Bioorganic and Medicinal Chemistry Letters. 2012 Jan | journal-article. doi: 10.1016/j.bmcl.2012.07.005.
Pyridone methylsulfone hydroxamate LpxC inhibitors for the treatment of serious Gram-negative infections, Journal of Medicinal Chemistry. 2012 Jan | journal-article. doi: 10.1021/jm2014875.
Total Synthesis of Dermostatin A, The Journal of Organic Chemistry. 2011 Oct | journal-article. doi: 10.1021/jo2012658.
Preparation, Gram-Negative Antibacterial Activity, and Hydrolytic Stability of Novel Siderophore-Conjugated Monocarbam Diols, ACS Medicinal Chemistry Letters. 2011 May | journal-article. doi: 10.1021/ml200012f.
Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis, Antimicrobial Agents and Chemotherapy. 2011 Jan | journal-article. doi: 10.1128/AAC.01179-10.
New analyses of MIC90 data to aid antibacterial drug discovery, MedChemComm. 2011 Jan | journal-article. doi: 10.1039/c1md00095k.
Pharmacokinetics and Whole‐Blood Bactericidal Activity againstMycobacterium tuberculosisof Single Doses of PNU‐100480 in Healthy Volunteers, The Journal of Infectious Diseases. 2010 Sep | journal-article. doi: 10.1086/655471.
Structure–activity relationships and hepatic safety risks of thiazole agonists of the thrombopoietin receptor, Bioorganic & Medicinal Chemistry Letters. 2010 Jul | journal-article. doi: 10.1016/j.bmcl.2010.05.087.
The identification of orally bioavailable thrombopoietin agonists, Bioorganic and Medicinal Chemistry Letters. 2009 Jan | journal-article. doi: 10.1016/j.bmcl.2009.01.032.
The Total Synthesis of the Oxopolyene Macrolide RK-397, Angewandte Chemie. 2007 Feb | journal-article. doi: 10.1002/ange.200602601.
The Total Synthesis of the Oxopolyene Macrolide RK-397, Angewandte Chemie International Edition. 2007 Feb | journal-article. doi: 10.1002/anie.200602601.
Chapter 9. Current Approaches to Tuberculosis Drug Discovery and Development, Neglected Diseases and Drug Discovery. 1 Jan | other. doi: 10.1039/9781849733496-00228.
Diastereoselectivity in the Protonation of Ester Enolates. The Importance of Aggregation with LDA, The Journal of Organic Chemistry. 1995 Jun | journal-article. doi: 10.1021/jo00116a046.